On May 29, 2013, Anacor Pharmaceuticals (ANAC) announced successful completion of pre-NDA (New Drug Application) communication with the United States Food and Drug Administration (FDA) related to tavaborole, Anacor's lead drug candidate for the treatment of onychomycosis. More recently, on July 26, 2013, Anacor indicated that it had submitted its NDA to the FDA. The FDA has sixty days to decide whether to accept this NDA for review. Based on analysis of scientific literature and clinical data on drug efficacy and safety, we believe the NDA for tavaborole will be accepted for review and will then be approved by mid-2014.
Anacor is a biopharmaceutical company with eight drug candidates in its pipeline. Its lead product candidates include...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: